DX & VX CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,410 KRW | +1.38% |
|
+2.56% | -25.38% |
| 2023 | Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS | CI |
| 2023 | Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers | CI |
| Sales 2022 | 32.18B 23.24M 1.86B | Sales 2023 | 46.75B 33.75M 2.7B | Capitalization | 179B 129M 10.33B |
|---|---|---|---|---|---|
| Net income 2022 | -780M -563K -45.13M | Net income 2023 | -27.48B -19.84M -1.59B | EV / Sales 2022 | 7.17 x |
| Net Debt 2022 | 8.61B 6.22M 498M | Net Debt 2023 | 27.25B 19.67M 1.58B | EV / Sales 2023 | 4.4 x |
| P/E ratio 2022 |
-285
x | P/E ratio 2023 |
-6.36
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.61% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.38% | ||
| 1 week | +2.56% | ||
| Current month | -11.71% | ||
| 1 month | -11.71% | ||
| 3 months | -16.95% | ||
| 6 months | -26.01% | ||
| Current year | -25.38% |
1 week
4 230.00
4 480.00
1 month
4 170.005 090.00
Current year
3 690.007 280.00
1 year
3 690.0010 050.00
3 years
3 690.0010 050.00
5 years
3 690.0010 050.00
10 years
3 266.6724 133.33
| Managers | Title | Age | Since |
|---|---|---|---|
Lee Yong-Gu
CEO | Chief Executive Officer | - | 15/05/23 |
Gyu-Chan Kwon
PSD | President | 54 | 15/05/23 |
Gang-Pyeong Lee
DFI | Director of Finance/CFO | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Do-Soon Hwang
BRD | Director/Board Member | 61 | - |
Wang-Jun Lee
CTO | Chief Tech/Sci/R&D Officer | 59 | 12/12/17 |
Baek-Seung Lee
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 4,410 | +1.38% | 69,856 |
| 29/04/24 | 4,350 | +0.12% | 30,372 |
| 26/04/24 | 4,345 | -0.23% | 27,419 |
| 25/04/24 | 4,355 | +1.04% | 44,820 |
| 24/04/24 | 4,310 | +1.17% | 63,406 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Dx & Vx Co Ltd, formerly Cancer Rop Co Ltd, is a Korea-based company primarily engaged in the molecular diagnosis business. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.38% | 96.29M | |
| -18.88% | 10.91B | |
| +53.75% | 3.3B | |
| -32.50% | 2.19B | |
| -14.31% | 2.16B | |
| -26.83% | 1.5B | |
| +28.55% | 1.09B | |
| -3.28% | 737M | |
| -23.50% | 404M | |
| -43.27% | 386M |
- Stock Market
- Equities
- A180400 Stock
